about
Temporal changes in prevalence of molecular markers mediating antimalarial drug resistance in a high malaria transmission setting in UgandaArtemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan childrenIntermittent preventive therapy with sulfadoxine-pyrimethamine for malaria in pregnancy: a cross-sectional study from Tororo, UgandaWhy is malaria associated with poverty? Findings from a cohort study in rural Uganda.Maternal nutritional status predicts adverse birth outcomes among HIV-infected rural Ugandan women receiving combination antiretroviral therapy.Multiplex, DNase-free one-step reverse transcription PCR for Plasmodium 18S rRNA and spliced gametocyte-specific mRNAs.Comparative impacts over 5 years of artemisinin-based combination therapies on Plasmodium falciparum polymorphisms that modulate drug sensitivity in Ugandan childrenArtemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan childrenIncreased risk of early vomiting among infants and young children treated with dihydroartemisinin-piperaquine compared with artemether-lumefantrine for uncomplicated malaria.Loss and dysfunction of Vδ2⁺ γδ T cells are associated with clinical tolerance to malaria.Protective efficacy of co-trimoxazole prophylaxis against malaria in HIV exposed children in rural Uganda: a randomised clinical trial.Effect of nutritional status on response to treatment with artemisinin-based combination therapy in young Ugandan children with malariaMind the gap: house structure and the risk of malaria in Uganda.Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infantsFactors associated with malaria parasitemia, anemia and serological responses in a spectrum of epidemiological settings in Uganda.Malaria transmission, infection, and disease at three sites with varied transmission intensity in Uganda: implications for malaria control.Decline of FoxP3+ Regulatory CD4 T Cells in Peripheral Blood of Children Heavily Exposed to MalariaThe association between malnutrition and the incidence of malaria among young HIV-infected and -uninfected Ugandan children: a prospective study.Novel serologic biomarkers provide accurate estimates of recent Plasmodium falciparum exposure for individuals and communitiesEffector Phenotype of Plasmodium falciparum-Specific CD4+ T Cells Is Influenced by Both Age and Transmission Intensity in Naturally Exposed PopulationsRethinking Dosing Regimen Selection of Piperaquine for Malaria Chemoprevention: A Simulation Study.Urban Malaria: Understanding its Epidemiology, Ecology, and Transmission Across Seven Diverse ICEMR Network Sites.Associations between urbanicity and malaria at local scales in Uganda.Measures of Malaria Burden after Long-Lasting Insecticidal Net Distribution and Indoor Residual Spraying at Three Sites in Uganda: A Prospective Observational Study.Estimating malaria parasite prevalence from community surveys in Uganda: a comparison of microscopy, rapid diagnostic tests and polymerase chain reaction.Increasing incidence of malaria in children despite insecticide-treated bed nets and prompt anti-malarial therapy in Tororo, UgandaImpact of Sulfadoxine-Pyrimethamine Resistance on Effectiveness of Intermittent Preventive Therapy for Malaria in Pregnancy at Clearing Infections and Preventing Low Birth WeightMeasuring Socioeconomic Inequalities in Relation to Malaria Risk: A Comparison of Metrics in Rural UgandaB cell sub-types following acute malaria and associations with clinical immunity.The effects of ACT treatment and TS prophylaxis on Plasmodium falciparum gametocytemia in a cohort of young Ugandan children.The cost-effectiveness of repeat HIV testing during pregnancy in a resource-limited setting.Characterizing microscopic and submicroscopic malaria parasitaemia at three sites with varied transmission intensity in Uganda.Population Pharmacokinetics and Pharmacodynamics of Lumefantrine in Young Ugandan Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria.Placental malaria among HIV-infected and uninfected women receiving anti-folates in a high transmission area of Uganda.IFNγ/IL-10 co-producing cells dominate the CD4 response to malaria in highly exposed children.Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected childrenSpatio-temporal analysis of malaria vector density from baseline through intervention in a high transmission setting.Early parasite clearance following artemisinin-based combination therapy among Ugandan children with uncomplicated Plasmodium falciparum malariaAvidity of anti-malarial antibodies inversely related to transmission intensity at three sites in Uganda.Drug resistance mediating Plasmodium falciparum polymorphisms and clinical presentations of parasitaemic children in Uganda
P50
Q28125904-040642F4-6BDB-4BBC-893B-404F53E51D7AQ28263182-9142B2B5-CC05-469C-9C19-992CDF67B4ABQ28536733-9E7FDFEC-FC50-4AB2-A70B-80F440733006Q30382407-9DA81C1F-8BF4-48F7-B487-E08DD01E63F2Q31081091-F315F7F2-1CC0-4ADE-9A57-6FFE7463768EQ33709137-479F4F03-A8B1-4A6B-BA53-2912B310BAACQ33947834-0BDFE0F9-3CE9-43FE-9EA2-8A7A6BC76D43Q34137766-48357675-DC9D-476A-8011-8A461C2EADF1Q34160147-A5857B7D-D730-428A-BFEC-85D8763A3322Q34343795-635F2A6D-8DFA-4AED-99C2-EFB694A50EECQ34748630-8880C5A2-BD5B-4406-A1F3-54BA80D4A973Q35004867-545D8AC6-99DD-447A-8F8F-201CEC340337Q35031819-E23CD66D-BE07-4416-995F-6CB6A385EC2EQ35055212-E880C749-84F4-4587-A32D-0A7326EDC1C4Q35174950-EEB7ACBD-CA9C-4A3D-A6C9-D76189DB333AQ35590729-C44A1D6C-0790-4D08-BEEA-E79E1E31B55EQ35693630-EEFAFF48-FFB0-430B-A26E-B2BC48BA9012Q35914418-1DE1CC26-78B8-4EAE-AEBB-DD84CACB5149Q35961275-EB072718-D508-43DE-98AC-D000353471E5Q35965247-AC075E56-A844-46FE-B39E-6D7FCE6C3907Q36018444-C1235D97-0330-4207-B03B-C71BB29D0880Q36071330-DE2A3EC8-E558-44F1-B3AE-AD7BFD763884Q36104916-F57EC8FA-E486-488E-B30B-7A2CC0857945Q36185615-CAC396BA-81F1-45FF-ADDB-D9A5859C7E3EQ36416969-4B3EA6CE-7641-41CC-83AD-AF2B7C9B835FQ36552347-765857BC-B114-4CF3-8BA8-695BDD3A3754Q36603993-EBC4882C-396D-4B3F-95B0-933828D785A0Q36644522-55DD185F-1277-4A74-BA91-E6E4AA51ABACQ36651730-A154B963-1D79-4F61-830A-661E4060A60AQ36743875-2B7023C0-CB66-4A44-8D49-163D79BD6E25Q36843894-70217999-7C8B-49A0-BDB9-8FC7D837E11EQ37258158-9298B9FA-4EDA-4B1A-A2D1-5AAF1B1EC01EQ37279764-5585F23C-D786-4FFD-9F3D-15FB4A05145BQ37429678-A0DDC98D-7F62-4BD4-B2D1-87455E1A6D74Q37458864-280520E9-A209-4C70-B943-F42D55EEBADDQ37460745-5B0504DE-D385-4276-833F-CBC5EA1FB4BCQ37498027-710A31D7-A748-4A51-AE69-01F5192851E9Q37539183-1EBE4DD2-CFD0-4E23-BB03-EAD7EE050328Q37635335-749888D6-FD8B-49B6-8C29-FC5585749C90Q37715709-F92A04C1-BFB2-4AA6-82C7-9C38F30377F6
P50
name
Emmanuel Arinaitwe
@ast
Emmanuel Arinaitwe
@en
Emmanuel Arinaitwe
@es
Emmanuel Arinaitwe
@nl
type
label
Emmanuel Arinaitwe
@ast
Emmanuel Arinaitwe
@en
Emmanuel Arinaitwe
@es
Emmanuel Arinaitwe
@nl
prefLabel
Emmanuel Arinaitwe
@ast
Emmanuel Arinaitwe
@en
Emmanuel Arinaitwe
@es
Emmanuel Arinaitwe
@nl